phosphorylcholine has been researched along with Angiogenesis, Pathologic in 8 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phosphorylcholine (PC) is one of the main oxLDL epitopes playing a central role in atherosclerosis, due to its atherogenic and proinflammatory effects." | 8.12 | Phosphorylcholine Monoclonal Antibody Therapy Decreases Intraplaque Angiogenesis and Intraplaque Hemorrhage in Murine Vein Grafts. ( Baganha, F; de Jong, RCM; de Vries, MR; Delibegovic, M; Jukema, JW; Peters, HAB; Pettersson, K; Quax, PHA; Sluiter, TJ; van Alst, LA, 2022) |
| "Treatment with perifosine for 5 weeks, alone and in combination with sorafenib, strongly inhibited tumor growth and increased survival." | 5.42 | Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. ( Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015) |
| "Phosphorylcholine (PC) is one of the main oxLDL epitopes playing a central role in atherosclerosis, due to its atherogenic and proinflammatory effects." | 4.12 | Phosphorylcholine Monoclonal Antibody Therapy Decreases Intraplaque Angiogenesis and Intraplaque Hemorrhage in Murine Vein Grafts. ( Baganha, F; de Jong, RCM; de Vries, MR; Delibegovic, M; Jukema, JW; Peters, HAB; Pettersson, K; Quax, PHA; Sluiter, TJ; van Alst, LA, 2022) |
| "Glioblastoma is a highly malignant brain tumor that relentlessly defies therapy." | 2.47 | Genetics of glioblastoma: a window into its imaging and histopathologic variability. ( Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA, 2011) |
| "Treatment with perifosine for 5 weeks, alone and in combination with sorafenib, strongly inhibited tumor growth and increased survival." | 1.42 | Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma. ( Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baganha, F | 1 |
| Sluiter, TJ | 1 |
| de Jong, RCM | 1 |
| van Alst, LA | 1 |
| Peters, HAB | 1 |
| Jukema, JW | 1 |
| Delibegovic, M | 1 |
| Pettersson, K | 1 |
| Quax, PHA | 1 |
| de Vries, MR | 1 |
| El-Sheridy, NA | 1 |
| El-Moslemany, RM | 1 |
| Ramadan, AA | 1 |
| Helmy, MW | 1 |
| El-Khordagui, LK | 1 |
| Giacomini, A | 1 |
| Righi, M | 1 |
| Cleris, L | 1 |
| Locatelli, SL | 1 |
| Mitola, S | 1 |
| Daidone, MG | 1 |
| Gianni, AM | 1 |
| Carlo-Stella, C | 1 |
| Kim, MN | 1 |
| Ro, SW | 1 |
| Kim, DY | 1 |
| Kim, da Y | 1 |
| Cho, KJ | 1 |
| Park, JH | 1 |
| Lim, HY | 1 |
| Han, KH | 1 |
| Cseh, A | 1 |
| Szebeni, B | 1 |
| Szalay, B | 1 |
| Vásárhelyi, B | 1 |
| Holland, WS | 1 |
| Tepper, CG | 1 |
| Pietri, JE | 1 |
| Chinn, DC | 1 |
| Gandara, DR | 1 |
| Mack, PC | 1 |
| Lara, PN | 1 |
| Wang, FZ | 1 |
| Fei, HR | 1 |
| Li, XQ | 1 |
| Shi, R | 1 |
| Wang, de C | 1 |
| Belden, CJ | 1 |
| Valdes, PA | 1 |
| Ran, C | 1 |
| Pastel, DA | 1 |
| Harris, BT | 1 |
| Fadul, CE | 1 |
| Israel, MA | 1 |
| Paulsen, K | 1 |
| Roberts, DW | 1 |
1 review available for phosphorylcholine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell S | 2011 |
7 other studies available for phosphorylcholine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Phosphorylcholine Monoclonal Antibody Therapy Decreases Intraplaque Angiogenesis and Intraplaque Hemorrhage in Murine Vein Grafts.
Topics: Animals; Antibodies, Monoclonal; Atherosclerosis; Hemorrhage; Humans; Male; Mice; Neovascularization | 2022 |
Enhancing the
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutica | 2021 |
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.
Topics: Analysis of Variance; Animals; Antigens, CD34; Blotting, Western; Cell Line, Tumor; DNA Primers; End | 2013 |
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma | 2015 |
[Akt enzyme: new therapeutic target in cancer and diabetes?].
Topics: Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Diabetes Mellitus; Enzyme Activ | 2009 |
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resist | 2012 |
Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells.
Topics: Antineoplastic Agents; Cell Line; Cell Movement; Cyclin B1; G2 Phase; Human Umbilical Vein Endotheli | 2012 |